Aggregometry in Elderlies With Hip Fracture and Receiving Clopidogrel
NCT04642209 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 9
Last updated 2020-11-24
Summary
In elderly patients, hip fracture should be surgically treated within 48 hours from admission, since its deferral worsens the mortality. However, sometimes patients are affected by cardiovascular or cerebral comorbidities, deeming necessary the use of antiplatelets and/or anticoagulant therapies. Clopidogrel is a second-generation thienopyridine antiplatelet drug which exerts its effect by the inhibition of the platelet's purinergic receptor P2Y12 preventing adenosine diphosphate (ADP) from stimulating it. Guidelines recommend to withhold clopidogrel for 5 days before the possibility to perform neuraxial anesthesia, which is frequently the optimal perioperative management of a fragile patient. It should be mentioned however that around 30% of patients are resistant to clopidogrel and they show a normal platelet reactivity despite the antiplatelet therapy. Therefore, in principle, these patients do not require to defer surgery. We have therefore hypothesized that some patients taking clopidogrel might anticipate surgery before 5 days and within 48 hours, following a protocol based on the assessment of coagulation and platelet aggregation through thromboelastography (TEG) in combination with an ADP Platelet Mapping assay kit.
After hospital admission for femur fracture, eligible patients would be evaluated by the anesthesiologist and the orthopedic physicians for anesthesia and surgery. Immediately a sample of blood should be collected for TEG with ADP Platelet Mapping test. If both MA-ADP and platelets aggregation (%) will be within normal values, the patient could be considered as candidate for immediate surgery (within 48 hours) with neuraxial anesthesia and ultrasound-guided antalgic femoral nerve block. If MA-ADP and/or platelets aggregation (%) are lower, risk for mortality should be assessed. If the patient would be considered at high risk for mortality, he/she would undergo to general anesthesia and peripheral antalgic block to not postpone surgery. Otherwise, surgery would be postponed until the normalization of both MA-ADP and platelet aggregation.
Conditions
- Hip Fractures
- Clopidogrel, Poor Metabolism of
- Anesthesia
Interventions
- DEVICE
-
Aggregometry
After evaluation at the Emergency Department the anesthesiologist immediately collects a sample of blood for TEG with ADP Platelet Mapping test. If both MA-ADP and platelets aggregation (%) are within normal values (i.e. ≥45 mm and ≥83%, respectively), the patient could be considered as candidate for immediate surgery (within 48 hours) with neuraxial anesthesia. If MA-ADP and/or platelets aggregation (%) are lower than normal values, the Nottingham Hip Fracture Score (NHFS) is computed, to predict the 30-day mortality after hip fracture surgery. If NHFS is ≥4 (high risk), the patient will undergo to general anesthesia and peripheral antalgic block, to perform surgery within 48 hours. In case of low risk for mortality (i.e. a NHFS \<4), surgery will be postponed until the normalization of both MA-ADP and platelet aggregation.
Sponsors & Collaborators
-
University Magna Graecia
lead OTHER
Principal Investigators
-
Federico Longhini, MD · Magna Graecia University, Anesthesia and Intensive Care Unit
Eligibility
- Min Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-12-01
- Primary Completion
- 2020-12-15
- Completion
- 2020-12-30
Countries
- Italy
Study Locations
More Related Trials
-
A Prospective muLticEnter Registry in chrONic coronARy synDrOme
NCT06198673 ·Status: NOT_YET_RECRUITING
-
Platelet Aggregation in Patients With Coronary Artery Disease and Kidney Dysfunction Taking Clopidogrel or Ticagrelor
NCT03039205 ·Status: COMPLETED ·Phase: PHASE2
-
Does Continued Use of Clopidogrel Into Surgery Cause Increased Perioperative Bleeding?
NCT01960296 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes
NCT03347435 ·Status: TERMINATED ·Phase: NA
-
Impact of Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Patients With High on Treatment Platelet Reactivity Undergoing Percutaneous Coronary Intervention
NCT01505790 ·Status: COMPLETED ·Phase: PHASE3
-
Ticagrelor vs Clopidogrel for Platelet Inhibition in Stenting for Cerebral Aneurysm
NCT02675205 ·Status: COMPLETED ·Phase: PHASE3
-
Monitoring Antiplatelet Drugs in Cardiac Arrest Patients
NCT05730114 ·Status: UNKNOWN
-
Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis
NCT01155765 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects
NCT03430661 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluating Additional Platelet Inhibition in Patients With High Platelet Reactivity Undergoing Percutaneous Coronary Intervention
NCT01339026 ·Status: TERMINATED ·Phase: PHASE4
-
Aspirin and Clopidogrel Reactivity in Patients With Critical Limb Ischemia (CLI)
NCT02094755 ·Status: COMPLETED
-
Platelet Aggregation During the Shift From Clopidogrel to Ticagrelor
NCT01795820 ·Status: COMPLETED ·Phase: NA
-
Clopidogrel Monotherapy in Patients With High Bleeding Risk
NCT05223335 ·Status: COMPLETED ·Phase: PHASE4
-
Atorvastatin and Clopidogrel HIgh DOse in Stable Patients With Residual High Platelet Activity
NCT01335048 ·Status: COMPLETED ·Phase: PHASE4
-
The Clopidogrel and Aspirin After Surgery for Coronary Artery Disease
NCT00776477 ·Status: UNKNOWN ·Phase: PHASE3
-
Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis
NCT02215993 ·Status: COMPLETED ·Phase: PHASE4
-
Residual Platelet Activity In Advanced Peripheral Artery Disease
NCT01627431 ·Status: UNKNOWN ·Phase: PHASE4
-
High Clopidogrel Dose Versus Prasugrel and Ticagrelor in High Reactive Stable Patients
NCT01543932 ·Status: COMPLETED ·Phase: PHASE3
-
Prasugrel Versus High Dose Clopidogrel in Patients With Stable Coronary Artery Disease and High Platelet Reactivity While on Chronic Clopidogrel Treatment
NCT01304472 ·Status: COMPLETED ·Phase: PHASE3
-
Platelet Function Monitoring in Patients Treated With Clopidogrel at the Time of Primary Percutaneous Coronary Angioplasty
NCT00827346 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease
NCT01260584 ·Status: COMPLETED ·Phase: PHASE4
-
Clopidogrel And Ticagrelor in Healthy Subjects
NCT02086903 ·Status: COMPLETED ·Phase: PHASE3
-
Platelet Function Assessment for Atherothrombotic Patients
NCT00513149 ·Status: UNKNOWN ·Phase: PHASE4
-
Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting
NCT01572623 ·Status: UNKNOWN ·Phase: PHASE4
-
Effect of Haemodialysis on the Efficacy of Antiplatelet Agents
NCT03330223 ·Status: UNKNOWN